Literature DB >> 27006437

Mycobacterial Peritonitis in CAPD Patients in Limpopo: A 6-Year Cumulative Report from a Single Center in South Africa.

Ramon A Tamayo-Isla1, Mauro Cuba de la Cruz2, Ikechi G Okpechi3.   

Abstract

South Africa has one of the highest incidences of tuberculosis (TB) worldwide due to the ongoing human immunodeficiency virus (HIV) epidemic. There are, however, no reports on peritonitis in continuous ambulatory peritoneal dialysis (CAPD) patients due to Mycobacterium tuberculosis in South Africa. The aim of this study is to discuss our experience of tuberculous peritonitis in CAPD patients from a rural endemic area of South Africa. This is a retrospective descriptive study of CAPD patients diagnosed with mycobacterium peritonitis infection from January 2008 to August 2014 at the Limpopo Kidney and Dialysis Centre (LKDC) in South Africa. The diagnosis of peritonitis was based on the International Society for Peritoneal Dialysis (ISPD) 2010 recommendations. Peritoneal fluid samples were collected in BACTEC Myco/F Lytic Culture Vials (Becton, Dickinson and Company, Dublin, Ireland). Tenckhoff catheter tips were sent for acid-fast bacilli (AFB) smear and TB culture. Mycobacterium infection was considered in patients with clinical features of peritonitis if 1) AFB smear or TB culture was positive or 2) if the patient was smear- or culture-negative but had suggestive radiological features of TB in the lungs or abdomen or 3) if the patient improved clinically following treatment with anti-tuberculous drugs. Of 170 patients on CAPD for the period reviewed, 12 (7.1%) were diagnosed and treated for mycobacterial peritonitis. There was an equal number of males and females, and all the patients were Black Africans with a mean age of 35.4 years (17-51 years). Eight of the 12 patients (66.7%) had had previous episodes of non-tuberculous peritonitis. Four patients (33.3%) had elevated white blood cell count (WCC) while 9 had higher polymorph count in the PD fluid than lymphocyte count. Mycobacterial organism was confirmed in 9/12 (75%), while the diagnosis was made on clinical and radiological features in the remaining 3 patients. Seven patients (58.3%) died, 10 patients were permanently transferred to hemodialysis (HD), 1 patient returned to PD after a short stay on HD, 1 patient died after 2 years on HD due to lack of further access to dialysis, and in 1 patient, the catheter could not be removed before death. This case series corroborates findings from other previous series that mycobacterial infection in PD patients carries a high mortality and can often pose a diagnostic challenge to attending clinicians. Clinicians should have a high index of suspicion for mycobacterial peritonitis in CAPD patients with features of peritonitis who do not respond promptly to conventional anti-microbial agents. We feel that the recommendation about catheter removal during mycobacterial peritonitis should be revisited, as it had no impact on our patients' outcome.
Copyright © 2016 International Society for Peritoneal Dialysis.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27006437      PMCID: PMC4803369          DOI: 10.3747/pdi.2014.00322

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  12 in total

1.  Peritoneal dialysis-related infections recommendations: 2010 update.

Authors:  Philip Kam-Tao Li; Cheuk Chun Szeto; Beth Piraino; Judith Bernardini; Ana E Figueiredo; Amit Gupta; David W Johnson; Ed J Kuijper; Wai-Choong Lye; William Salzer; Franz Schaefer; Dirk G Struijk
Journal:  Perit Dial Int       Date:  2010 Jul-Aug       Impact factor: 1.756

2.  Tuberculous peritonitis: a race against time.

Authors:  N Vadivel; J K Tucker; S Trikudanathan; E Heher; A K Singh
Journal:  Kidney Int       Date:  2006-07-05       Impact factor: 10.612

Review 3.  Tuberculous peritonitis.

Authors:  Tekin Akpolat
Journal:  Perit Dial Int       Date:  2009-02       Impact factor: 1.756

4.  Tuberculous peritonitis in a cohort of continuous ambulatory peritoneal dialysis patients.

Authors:  G Abraham; M Mathews; L Sekar; A Srikanth; U Sekar; P Soundarajan
Journal:  Perit Dial Int       Date:  2001       Impact factor: 1.756

5.  Tuberculosis infection in Chinese patients undergoing continuous ambulatory peritoneal dialysis.

Authors:  S L Lui; S Tang; F K Li; B Y Choy; T M Chan; W K Lo; K N Lai
Journal:  Am J Kidney Dis       Date:  2001-11       Impact factor: 8.860

6.  Malnutrition, altered immune function, and the risk of infection in maintenance hemodialysis patients.

Authors:  W D Mattern; L J Hak; R W Lamanna; K M Teasley; M S Laffell
Journal:  Am J Kidney Dis       Date:  1982-01       Impact factor: 8.860

7.  Eleven years of experience with dialysis associated tuberculosis.

Authors:  G H Malik; A S Al-Harbi; S Al-Mohaya; H Al-Khawajah; M Kechrid; A Osman Al Hassan; K Balbaid; M Sabry Shetia
Journal:  Clin Nephrol       Date:  2002-11       Impact factor: 0.975

8.  Tuberculous peritonitis associated with peritoneal dialysis.

Authors:  Abdelkarim Waness; Saad Al Shohaib
Journal:  Saudi J Kidney Dis Transpl       Date:  2012-01

Review 9.  Tuberculous peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: case report and review.

Authors:  R Talwani; J A Horvath
Journal:  Clin Infect Dis       Date:  2000-07-24       Impact factor: 9.079

10.  The prevalence and clinical features of tuberculous peritonitis in CAPD patients in Turkey, report of ten cases from multi-centers.

Authors:  Ibrahim Karayaylali; Neslihan Seyrek; Tekin Akpolat; Kenan Ateş; Cetin Ozener; Mehmet Emin Yilmaz; Cengiz Utas; Mahmut Yavuz; Fehmi Akcicek; s Turgay Arinsoy; Rezzan Ataman; Semra Bozfakioglu; Taner Camsari; Fevzi Ersoy
Journal:  Ren Fail       Date:  2003-09       Impact factor: 2.606

View more
  1 in total

1.  Bone and joint tuberculosis in patients undergoing dialysis: clinical features, risk factors, and outcomes in 17 patients.

Authors:  Xuehua Wu; Jing Liu; Guorong Wang; Fengfeng Wu
Journal:  J Int Med Res       Date:  2020-08       Impact factor: 1.671

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.